1,1-Dimethyl 3-(phenylmethoxy)-1,1-cyclobutanedicarboxylate | 1197238-00-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1,1-Dimethyl 3-(phenylmethoxy)-1,1-cyclobutanedicarboxylate
• 英文别名: dimethyl 3-phenylmethoxycyclobutane-1,1-dicarboxylate
• CAS: 1197238-00-8
• 化学式: C₁₅H₁₈O₅
• 分子量: 278.305
• InChiKey: FRJXAFHMUHRXLG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  20
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  61.8
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  1,1-Dimethyl 3-(phenylmethoxy)-1,1-cyclobutanedicarboxylate 在 lithium aluminium tetrahydride 作用下， 以 乙醚 为溶剂， 以47%的产率得到1-benzyloxy-3,3-bis(hydroxymethyl)cyclobutane
  参考文献：
  名称：

  Design and synthesis of spirocyclic compounds as HCV replication inhibitors by targeting viral NS4B protein

  摘要：

  Two novel series of spirocyclic piperidine analogs appended to a pyrazolo[1,5-alpha] pyridine core were designed, synthesized and evaluated for their anti-HCV activity. A series of piperidine ketals afforded dispiro 6p which showed excellent in vitro anti-HCV activities (EC50 of 1.5 nM and 1.2 nM against genotype 1a and 1b replicons, respectively). A series of piperidine oxazolidinones afforded 27c which showed EC50's of 10.9 nM and 6.1 nM against 1a and 1b replicons, respectively. Both compounds 6p and 27c bound directly to non-structural NS4B protein in vitro (IC50's = 10.2 and 30.4 nM, respectively) and exhibited reduced potency in replicons containing resistance mutations encoding changes in the NS4B protein. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.03.080

文献信息

• Design and synthesis of spirocyclic compounds as HCV replication inhibitors by targeting viral NS4B protein
  作者：Vincent W.-F. Tai、Dulce Garrido、Daniel J. Price、Andrew Maynard、Jeffrey J. Pouliot、Zhiping Xiong、John W. Seal、Katrina L. Creech、Luz H. Kryn、Todd M. Baughman、Andrew J. Peat

  DOI：10.1016/j.bmcl.2014.03.080

  日期：2014.5

  Two novel series of spirocyclic piperidine analogs appended to a pyrazolo[1,5-alpha] pyridine core were designed, synthesized and evaluated for their anti-HCV activity. A series of piperidine ketals afforded dispiro 6p which showed excellent in vitro anti-HCV activities (EC50 of 1.5 nM and 1.2 nM against genotype 1a and 1b replicons, respectively). A series of piperidine oxazolidinones afforded 27c which showed EC50's of 10.9 nM and 6.1 nM against 1a and 1b replicons, respectively. Both compounds 6p and 27c bound directly to non-structural NS4B protein in vitro (IC50's = 10.2 and 30.4 nM, respectively) and exhibited reduced potency in replicons containing resistance mutations encoding changes in the NS4B protein. (C) 2014 Elsevier Ltd. All rights reserved.